Sources say Sun Pharmaceutical Industries, which announced Monday that it is taking over Ranbaxy Laboratories, could phase out the Ranbaxy brand of generic drugs by the end of the year over quality issues. Sun Pharma's senior vice president of finance and accounts, Uday Baldota, said the Ranbaxy brand "has a value" and will be used and preserved. Pharmaceutical and branding experts called Ranbaxy a "damaged brand" and said it would be best for Sun to drop it. Sun Pharma officials said their biggest priority is bringing Ranbaxy's four manufacturing firms in India into compliance with U.S. FDA standards.
Published in Brief: